Solaris Endovascular today announced its formation to develop solutions for dialysis access and treating peripheral artery ...

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

More recently, drug-eluting stents (DESs) have emerged as the predominant ... Optimal Management of Multivessel Disease [FREEDOM] and Synergy Between PCI With TAXUS ® and Cardiac Surgery [SYNTAX ...

Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

The CLEAR SYNERGY (OASIS 9) study, called "the largest trial ever ... More than 95% of patients were implanted with a drug-eluting stent. At month 3, C-reactive protein levels were significantly lower ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

You’ll usually need to continue dual antiplatelet drug therapy for a year after a drug-eluting stent placement and a month after a bare-metal stent placement. Drug-eluting stents are a newer ...

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

The use of drug-eluting stents (DES) has become widespread as a result of their superior revascularization rates compared with those of bare-metal stents (BMS). 1 DES are increasingly being used ...

Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting ... everolimus-eluting stents. In addition, in Europe, it markets the SYNERGY Everolimus ...

Non-drug eluting devices, such as bare-metal stents, catheters, and implantable medical devices, are widely used in procedures where drug elution is not necessary, or where a more mechanical or ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD). The data, which was presented as a ...